Please type a plus sign (+) inside this box → PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respo Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)

2

of

Sheet

1


sond to a collection of information uni	ess it contains a valid OMB con	ro Aun	ıber.
Сотр	lete if Known	呈	S
Application Number	09/807,332	8	T
Filing Date	April 11, 2001		
First Named Inventor	Thomas G. Burk		-24
Group Art Unit			-1
Examiner Name		중	
Attomey Docket Number	434-204	S	
		_	_

U.S. PATENT DOCUMENTS						
xaminer nitials*	Cite No.1	U.S. Patent Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant
0	1	5,552,15	6	Burke	09/03/1996	Figures Appear
\rightarrow	2	5,736,15		Burke	04/07/1998	
+	3	5,726,18		Hausheer et al.	03/10/1998	
+	4	5,714,17		Baserga et al.	02/03/1998	
+-+	5	5,677,28		Shull et al.	10/14/1997	
\dashv	6	5,674,87	3	Hausheer et al.	10/07/1997	
	7	5,651,98		Brem et al.	07/29/1997	
+	8	5,604,23		Hausheer et al.	02/18/1997	
+	9	5,583,03		Green et al.	12/10/1996	
#	10	5,447,93	6	Hausheer et al.	09/05/1995	
·	11	5,276,01	9	Cohen et al.	01/04/1994	7
			-			
	_					
$-\!$						
	f					

	FOREIGN PATENT DOCUMENTS							
Examiner Cite	Foreign Patent Document				Date of Publication of	Pages, Columns, Lines,	$\overline{}$	
Initials	No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T6
				1 1				1
						 		+-
						 		╀
						 		₩.
								╄
		 						
								T
								1
								+-

Examiner Signature	Dar	Date Considered Clivio
SEVANDED A SILVE		Considered

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Į	J
Γ	T	1
()
ſ	T	1
<	-	7
Γ	T	Ì
C	_	3

	der the Paperwork Reduction Act of 1995, no persons are required to re-	Appi Patent and Tradems spond to a collection of informatio	PTO/SB/08B roved for use through 10/31/99. OMB 06 ark Office: U.S. DEPARTMENT OF COM n unless it contains a valid OMB control	
JUL 1 6 2001 H	Substitute for form 1449B/PTO	Complete if Known		
\\$. \\\2.	INFORMATION DISCLOSURE	Application Number	09/807,332	\Box
(g) at 0		Filing Date	April 11, 2001	Z
PRADEMARKS TRADEMARKS	STATEMENT BY APPLICANT	First Named Inventor	Thomas G. Burke	

(use as many sheets as necessary)

Sheet 2 Attorney Docket Number 434-204 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Cite Examiner item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Initials* No 3 T2 JAXEL et al., Effect of Local DNA sequence on Topoisomerase I Cleavage in the 0 Presence or Absence of Camptothecin. The Journal of Biological Chemistry. 25 October 1991, Vol. 266, No. 30, pages 20418-20423, especially the abstract. Database Caplus on STN, AN 1997:725569, FLEURY et al. Conformation and mechanism in DNA-topoisomerase I as a target of antitumor drugs: optical spectroscopy approach. Spectrosc Biol Mol. Mod. Trends, 1997, Eur. Conf. 7th, Conference Abstet. LETEURTRE et al. Specific Interaction of Camptothecin, a Topoisomerase I Inhibitor, with Guanine Residues of DNA detected by Photoactivation at 365 nm. Biochemistry. 1993. Vol. 32, pages 8955-8962, especially abstract. GIOVANELLA, et al., DNA Topoisomerase I-Targeted Chemotherapy of Human Colon Cancer in Xenografts, Science 246: 1046-1048 (Washington, DC) (1989) MADDEN, T.D., BURKE, T.G., REDELMEIER, T.E. and BALLY, M.B., "Encapsulation of Topotecan in Lipid-Based Carriers: Evaluation of Drug Stability and 5 Plasma Elimination in a Murine Model", Proc. Am. Soc. Clin. Oncol., 17: 196a (1998)

Group Art Unit

Examiner Name

Examiner Signature	Dalh	Date	2/12/27
	JAIW	Considered	LIUINOZ

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.